Sat Kartar Shopping Limited, an Ayurveda-focused healthcare company, is launching its SME Initial Public Offering Sat Kartar Shopping IPO to raise ₹33.80 crore through a fresh issue of 41.73 lakh shares. The IPO is scheduled to open on January 10, 2025, and close on January 14, 2025, with shares expected to list on the NSE SME platform on January 17, 2025.
Key Details of the Sat Kartar Shopping IPO:
- Price Band: ₹77 to ₹81 per share.
- Lot Size: 1,600 shares, requiring a minimum investment of ₹1,29,600 at the upper price band.
- Issue Size: ₹33.80 crore through a fresh issue of 41.73 lakh shares.
IPO Timeline:
- Opening Date: January 10, 2025.
- Closing Date: January 14, 2025.
- Basis of Allotment: January 15, 2025.
- Initiation of Refunds: January 16, 2025.
- Credit of Shares to Demat Accounts: January 16, 2025.
- Listing Date: January 17, 2025.
Reservation Details:
- Retail Individual Investors (RII): Not less than 35% of the Net Issue.
- Non-Institutional Investors (NII): Not more than 15% of the Net Issue.
Company Overview:
Incorporated in June 2012, Sat Kartar Shopping Limited specializes in Ayurveda-based healthcare products, offering a range of therapeutic and lifestyle solutions. The company’s product portfolio includes remedies for addiction, diabetes management, joint pain relief, and personal care. Sat Kartar Shopping operates on a direct-to-consumer (D2C) model, utilizing its website, third-party e-commerce platforms, television marketing, and digital channels for product distribution.
Who Is The Owner Of Sat Kartar Shopping
Sat Kartar Shopping Limited was founded by Mr. Manprit Singh Chadha, whose passion for Ayurveda led to the establishment of the company.
Mr. Ved Prakash – Managing Director
Mr. Sanjay Kumar – Director
Mr. Sunil Kumar Mehdiratta – Director
Mr. Manoj Kumar Verma – Director
Ms. Richa Takkar – Director
Mr. Steve Austin Pereira – Independent Director
Mr. Pranav Singh Chadha – Director
Ms. Simrati Kaur – Director
Mr. Devender Kumar Arora – Chief Financial Officer
Ms. Himanshu Malik – Company Secretary & Compliance Officer
Specific details about the current ownership structure, including the distribution of shares among founders, directors, and other shareholders, are not publicly available. For the most accurate and up-to-date information, it is advisable to refer to the company’s official communications or regulatory filings.
Financial Highlights:
Revenue from Operations:
- FY2022: ₹51.92 crore.
- FY2023: ₹82.97 crore.
- FY2024: ₹127.91 crore.
Profit After Tax (PAT):
- FY2022: ₹1.39 crore.
- FY2023: ₹2.51 crore.
- FY2024: ₹6.30 crore
Objectives of the IPO:
- Funding acquisitions (domestic or international).
- Marketing and advertising expenses.
- Capital expenditure.Investment in technology.
- General corporate purposes.
How to Apply:
Investors can apply for the Sat Kartar Shopping IPO through various brokerage platforms by:
- Logging into their trading account.
- Navigating to the IPO section.
- Selecting the Sat Kartar Shopping IPO.
- Entering the bid quantity and price.
- Submitting the application and approving the UPI mandate for payment.
Registrar and Lead Manager:
- Registrar: Skyline Financial Services Private Ltd.
- Lead Manager: Narnolia Financial Services Ltd.
Investors are advised to review the company’s financials, objectives, and risk factors before making investment decisions.
Company Strengths:
(1) Growing Market Segment:
Sat Kartar Shopping operates in the Ayurveda-based healthcare sector, a growing market fueled by increasing consumer preference for natural and holistic health solutions.
(2) Diversified Product Portfolio:
The company offers a wide range of products targeting various health concerns, including addiction, diabetes, joint pain, and personal care. This diversification reduces dependency on a single product line.
(3) Direct-to-Consumer (D2C) Model:
A strong D2C presence through its website, third-party e-commerce platforms, television marketing, and digital channels ensures better control over margins and customer engagement.
(4) Revenue Growth:
The company has shown significant revenue growth:
- FY2022: ₹51.92 crore
- FY2023: ₹82.97 crore
- FY2024: ₹127.91 crore
(5) Improved Profitability:
Profit After Tax (PAT) increased from ₹1.39 crore in FY2022 to ₹6.30 crore in FY2024, showcasing strong financial performance.
IPO Highlights:
- Lot Size: 1,600 shares (₹1,29,600 minimum investment).
- Use of Proceeds: Funding acquisitions, marketing expenses, technology investment, and general corporate purposes.
- Listing: NSE SME platform.
Should You Invest?
Who Might Consider It:
- Investors with a high-risk appetite looking for exposure to the Ayurveda and healthcare sector.
- Those familiar with SME IPOs and willing to hold the investment long-term despite potential liquidity issues.
Who Should Avoid It:
- Conservative investors or those unfamiliar with SME IPO risks.
- Those uncomfortable with high valuations and low market liquidity.
Final Verdict:
The company shows promise due to its sector focus, D2C model, and revenue growth. However, the high valuation and risks associated with SME IPOs make it suitable only for seasoned investors with the capacity to tolerate volatility. Conduct thorough research or consult a financial advisor before making an investment decision.
Barflex Polyfilms IPO: Everything You Need To Know
Quadrant Future Tek Limited IPO: All You Need to Know Before Investing
Delta Autocorp IPO 2025: Should You Invest? Complete Review
Disclaimer: The content on this website is intended for informational purposes only and should not be interpreted as financial or investment advice. Engaging in stock market activities involves inherent risks, and outcomes can be unpredictable. While we strive to provide accurate and up-to-date information, we do not make any guarantees regarding the completeness or reliability of the content. Any investment decisions you make should be based on your own research and consultation with a qualified financial professional. We are not responsible for any financial gains or losses resulting from actions taken based on the information provided here. Always invest wisely and at your own risk.
